Thrombophilia and outcome in severe infection and sepsis

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 6, 2007, Pages 604-609

  Hofstra, Jorrit Jan ^a   Marcel Schouten, M D ^a   Levi, Marcel ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Antithrombin; Coagulation; Factor V Leiden; Infection; Plasminogen activator inhibitor type 1; Protein C; Sepsis; Thrombophilia

Indexed keywords

ALCOHOL; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5 LEIDEN; FIBRINOGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; TUMOR NECROSIS FACTOR ALPHA;

ALCOHOL CONSUMPTION; BACTERIAL GROWTH; CEREBROVASCULAR ACCIDENT; DNA POLYMORPHISM; ENDOTOXEMIA; FIBRINOLYSIS; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HETEROZYGOSITY; HUMAN; LOBAR PNEUMONIA; MENINGOCOCCEMIA; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; SEPSIS; SEPTIC SHOCK; SMOKING; THROMBOPHILIA;

FACTOR V; FIBRINOLYSIS; HUMANS; INFECTION; POLYMORPHISM, GENETIC; PROTEIN C; SEPSIS; THROMBOPHILIA; TREATMENT OUTCOME; VARIATION (GENETICS);

EID: 34548760188     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-985757     Document Type: Review

References (52)

1. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340:207-214
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-1554
3. Levi M. Current understanding of disseminated intravascular coagulation. Br J Haematol 2004;124:567-576
4. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586-592
5. Colman RW, Robboy SJ, Minna JD. Disseminated intravascular coagulation: a reappraisal. Annu Rev Med 1979;30:359-374
6. Marder VJ, Feinstein DI, Colman RW, Levi M. Consumptive thrombohemorrhagic disorders. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: J.B. Lippincott; 2006: 1571-1600
7. Levi M, van Gorp E, ten Cate H. Disseminated intravascular coagulation. In: Handin RI, Lux SE, Stossel TP, eds. Blood: Principles and Practice of Hematology. Philadelphia, PA: J.B. Lippincott; 2002:1275-1301
8. Levi M, de Jonge E, van der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis 2003;16:43-47
9. Levi M, Keller TT, van Gorp E, ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc Res 2003;60:26-39
10. Robboy SJ, Major MC, Colman RW, Minna JD. Pathology of disseminated intravascular coagulation (DIC). Analysis of 26 cases. Hum Pathol 1972;3:327-343
11. Shimamura K, Oka K, Nakazawa M, Kojima M. Distribution patterns of microthrombi in disseminated intravascular coagulation. Arch Pathol Lab Med 1983;107:543-547
12. Coalson JJ. Pathology of Sepsis, Septic Shock, and Multiple Organ Failure. Perspective on Sepsis and Septic Shock. Fullerton, CA: Society of Critical Care Medicine; 1986:27-59
13. Creasey AA, Chang AC, Feigen L, et al. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993;91:2850-2856
14. Kessler CM, Tang Z, Jacobs HM, Szymanski LM. The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood 1997;89:4393-4401
15. Taylor FBJ, Chang A, Ruf W, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991;33:127-134
16. Taylor FBJ, Chang A, Esmon CT, et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79:918-925
17. Welty-Wolf KE, Carraway MS, Miller DL, et al. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med 2001;164:1988-1996
18. Miller DL, Welty-Wolf K, Carraway MS, et al. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol 2002;26:650-658
19. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816-823
20. Dhainaut JF, Yan SB, Joyce DE, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004;2:1924-1933
21. Inbal A, Kenet G, Zivelin A, et al. Purpura fulminans induced by disseminated intravascular coagulation following infection in 2 unrelated children with double heterozygosity for factor V Leiden and protein S deficiency. Thromb Haemost 1997;77:1086-1089
22. Dogan Y, Aygun D, Yilmaz Y, et al. Severe protein S deficiency associated with heterozygous factor V Leiden mutation in a child with purpura fulminans. Pediatr Hematol Oncol 2003;20:1-5
23. al Ismail S, Collins P, Najib R, James-Ellison M, O'Hagan M. Postinfection purpura fulminans in a patient heterozygous for prothrombin G20210A and acquired protein S resistance. Pediatr Hematol Oncol 1999;16:561-564
24. Woods CR, Johnson CA. Varicella purpura fulminans associated with heterozygosity for factor V Leiden and transient protein S deficiency. Pediatrics 1998;102:1208-1210
25. Sackesen C, Secmeer G, Gurgey A, et al. Homozygous factor V Leiden mutation in a child with meningococcal purpura fulminans. Pediatr Infect Dis J 1998;17:87
26. Texereau J, Pene F, Chiche JD, Rousseau C, Mira JP. Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med 2004;32:S313-S319
27. Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001;29:S90-S94
28. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
29. Lay AJ, Liang Z, Rosen ED, Castellino FJ. Mice with a severe deficiency in protein C display prothrombotic and proinflammatory phenotypes and compromised maternal reproductive capabilities. J Clin Invest 2005;115:1552-1561
30. Jalbert LR, Rosen ED, Moons L, et al. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest 1998;102: 1481-1488
31. Levi M, Dorffler-Melly J, Reitsma PH, et al. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein C deficient mice. Blood 2003;101:4823-4827
32. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004;109:2698-2704
33. Lay AJ, Donahue D, Tsai MJ, Castellino FJ. Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency. Blood 2007;109:1984-1991
34. Ganopolsky JG, Castellino FJ. A protein C deficiency exacerbates inflammatory and hypotensive responses in mice during polymicrobial sepsis in a cecal ligation and puncture model. Am J Pathol 2004;165:1433-1446
35. Mesters RM, Mannucci PM, Coppola R, et al. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996;88:881-886
36. Minnema MC, Chang AC, Jansen PM, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000;95:1117-1123
37. Yanada M, Kojima T, Ishiguro K, et al. Impact of antithrombin deficiency in thrombogenesis: lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombin-deficient mice. Blood 2002;99:2455-2458
38. Kondaveeti S, Hibberd ML, Booy R, Nadel S, Levin M. Effect of the factor V Leiden mutation on the severity of meningococcal disease. Pediatr Infect Dis J 1999;18:893-896
39. Kerlin BA, Yan SB, Isermann BH, et al. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 2003;102:3085-3092
40. Bruggemann LW, Schoenmakers SH, Groot AP, Reitsma PH, Spek CA. Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice. Crit Care Med 2006;34:2201-2206
41. Bernard GR, Margolis BD, Shanies HM, et al. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 2004;125:2206-2216
42. Yan SB, Nelson DR. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Crit Care Med 2004;32:S239-S246
43. Benfield TL, Dahl M, Nordestgaard BG, Tybjaerg-Hansen A. Influence of the factor V Leiden mutation on infectious disease susceptibility and outcome: a population-based study. J Infect Dis 2005;192:1851-1857
44. Weiler H, Kerlin B, Lytle MC, Factor V. Leiden polymorphism modifies sepsis outcome: evidence from animal studies. Crit Care Med 2004;32:S233-S238
45. van der Poll T, Levi M, Buller HR, et al. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991;174:729-732
46. Biemond BJ, Levi M, ten Cat H, et al. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci 1995;88:587-594
47. Yamamoto K, Loskutoff DJ. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest 1996;97:2440-2451
48. Pinsky DJ, Liao H, Lawson CA, et al. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest 1998;102:919-928
49. Haralambous E, Hibberd ML, Hermans PW, et al. Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children. Crit Care Med 2003;31:2788-2793
50. Hermans PW, Hibberd ML, Booy R, et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999;354:556-560
51. Westendorp RG, Hottenga JJ, Slagboom PE. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999;354:561-563
52. Geishofer G, Binder A, Muller M, et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcaemia. Eur J Pediatr 2005;164:486-490